HK1164731A1 - Contrast agents for myocardial perfusion imaging - Google Patents

Contrast agents for myocardial perfusion imaging

Info

Publication number
HK1164731A1
HK1164731A1 HK12105633.8A HK12105633A HK1164731A1 HK 1164731 A1 HK1164731 A1 HK 1164731A1 HK 12105633 A HK12105633 A HK 12105633A HK 1164731 A1 HK1164731 A1 HK 1164731A1
Authority
HK
Hong Kong
Prior art keywords
contrast agents
myocardial perfusion
perfusion imaging
imaging
myocardial
Prior art date
Application number
HK12105633.8A
Other languages
English (en)
Chinese (zh)
Inventor
戴維．
．卡斯比爾
西蒙．
．魯濱遜
阿杰伊．普羅希特
海克．
．拉德克
邁克爾．
．阿澤爾
道格拉斯．
．迪斯奇諾
Original Assignee
蘭休斯醫療成像公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 蘭休斯醫療成像公司 filed Critical 蘭休斯醫療成像公司
Publication of HK1164731A1 publication Critical patent/HK1164731A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Acoustics & Sound (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HK12105633.8A 2004-02-13 2012-06-08 Contrast agents for myocardial perfusion imaging HK1164731A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54486104P 2004-02-13 2004-02-13
US11/055,498 US7344702B2 (en) 2004-02-13 2005-02-10 Contrast agents for myocardial perfusion imaging

Publications (1)

Publication Number Publication Date
HK1164731A1 true HK1164731A1 (en) 2012-09-28

Family

ID=34889838

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105633.8A HK1164731A1 (en) 2004-02-13 2012-06-08 Contrast agents for myocardial perfusion imaging

Country Status (19)

Country Link
US (7) US7344702B2 (ro)
EP (2) EP3385253B1 (ro)
JP (3) JP5417578B2 (ro)
KR (2) KR101186449B1 (ro)
CN (2) CN102274527B (ro)
AU (1) AU2005214898C1 (ro)
BR (1) BRPI0507684B8 (ro)
CA (3) CA2944947A1 (ro)
DK (2) DK1713512T3 (ro)
ES (2) ES2665687T3 (ro)
HK (1) HK1164731A1 (ro)
IL (4) IL177275A0 (ro)
IN (1) IN2012DN02610A (ro)
MX (1) MX348859B (ro)
NO (2) NO344857B1 (ro)
PT (1) PT1713512T (ro)
RU (2) RU2457865C2 (ro)
SG (1) SG149895A1 (ro)
WO (1) WO2005079391A2 (ro)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
US8926945B2 (en) * 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
WO2008009078A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
KR101810348B1 (ko) 2006-12-26 2017-12-18 랜티우스 메디컬 이메징, 인크. 심장 신경 분포의 영상화를 위한 리간드
WO2008128058A1 (en) * 2007-04-13 2008-10-23 The Trustees Of The University Of Pennsylvania New gallium bisaminothiolate complexes for myocardial imaging
ES2767973T3 (es) * 2008-02-29 2020-06-19 Lantheus Medical Imaging Inc Agentes de contraste para aplicaciones que comprenden formación de imágenes de perfusión
AU2015200027B2 (en) * 2008-02-29 2017-01-19 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
BRPI0910525A2 (pt) * 2008-07-09 2015-09-29 Koninkl Philips Electronics Nv agente de contraste para a formação de imagem f19 mri e nuclear concomitantes, aparelho de diagnóstico de imagem para imagem de contraste realçado, método de diagnostico por imagem, processador programado para controlador um scanner híbrido de ressonância magnética e tomografia de emissão de pósitron, software que contém midia que pode ser lida por computador, e, aparelho de formação de imagem médica para a geração de imagens realçadas de contraste.
CN107261159B (zh) * 2009-04-15 2021-01-12 兰休斯医疗成像公司 使用抗坏血酸稳定化放射性药物组合物
JP2012532833A (ja) * 2009-07-11 2012-12-20 バイエル ファーマ アクチエンゲゼルシャフト 非極性及び極性脱離基
EP2289889A1 (en) * 2009-08-18 2011-03-02 Endura S.p.a. Substituted alkynyl phenoxy compounds and their uses
CN101993383A (zh) * 2009-08-26 2011-03-30 成都伊诺达博医药科技有限公司 决奈达隆关键中间体4-[3-(二丁氨基)丙氧基]苯甲酸甲酯的新合成方法
TWI589302B (zh) 2010-02-08 2017-07-01 藍瑟斯醫學影像公司 用於合成造影劑及其中間體之方法及裝置
TWI592391B (zh) 2010-05-11 2017-07-21 藍瑟斯醫學影像公司 用於合成及使用造影劑之組合物、方法及系統
CN102038964B (zh) * 2010-12-30 2012-01-25 上海师范大学 一种非晶态铁钴硼纳米磁共振造影剂材料及其制备方法
CA2848147C (en) 2011-09-09 2021-08-24 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
AU2011379346B2 (en) * 2011-10-21 2017-08-31 Lantheus Medical Imaging, Inc. Compositions comprising ascorbic acid and an imaging agent and related methods
MX356258B (es) * 2011-12-22 2018-05-16 Respiratorius Ab Agente de contraste para obtener imágenes de la perfusión miocárdica.
CN104244991A (zh) 2012-04-10 2014-12-24 蓝瑟斯医学影像公司 放射性药物合成方法
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CN104583192B (zh) * 2012-08-24 2016-10-12 浜松光子学株式会社 适合于线粒体复合体-1检出的化合物
KR102233327B1 (ko) * 2013-12-26 2021-03-26 스미또모 가가꾸 가부시끼가이샤 할로겐 치환 프탈리드의 제조 방법
US9745308B2 (en) 2014-09-12 2017-08-29 Chiesi Farmaceutici S.P.A. Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors
KR101756050B1 (ko) 2015-03-04 2017-07-07 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
US20200009273A1 (en) * 2017-03-07 2020-01-09 Nihon Medi-Physics Co., Ltd. Radioactive fluorine-labeled precursor compound, and method for producing radioactive fluorine-labeled compound using same
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
CN111320620A (zh) * 2020-03-17 2020-06-23 四川大学华西医院 一种异喹啉并哒嗪酮类化合物及其合成方法和应用
CN116082670B (zh) * 2023-04-11 2023-06-27 中国人民解放军军事科学院军事医学研究院 一种含有季膦盐的声响应假性共轭聚合物纳米颗粒的制备方法及其在抗菌领域的应用

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1073999A (en) 1965-01-29 1967-06-28 Ncr Co Process for forming stable images in photochromic material
JPS5888334A (ja) * 1981-11-20 1983-05-26 Takasago Corp ３−ｌ−メントキシプロパン−１、２−ジオ−ル
US4510125A (en) 1982-12-08 1985-04-09 Mallinckrodt, Inc. Process for making lyophilized radiographic imaging kit
JPS604173A (ja) 1983-06-23 1985-01-10 Nissan Chem Ind Ltd ピリダジノン誘導体，その製造法および殺虫・殺ダニ・殺菌剤
DE3574870D1 (de) 1984-06-23 1990-01-25 Nissan Chemical Ind Ltd Verfahren zu herstellung von 2-tert.-butyl-4,5-dichloro-3(2h)-pyridazinon.
JPH07116161B2 (ja) 1984-07-04 1995-12-13 日産化学工業株式会社 ピリダジノン誘導体
DE3578304D1 (de) 1984-11-29 1990-07-26 Nissan Chemical Ind Ltd Pyridazinonderivate, deren herstellung und insektizidische, acaricidische, nematicidische, fungizidische zusammensetzungen.
JPS61130275A (ja) 1984-11-29 1986-06-18 Nissan Chem Ind Ltd ピリダジノン誘導体，その製造法および殺虫・殺ダニ・殺菌剤
EP0186817B1 (en) 1984-12-10 1989-08-02 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
US5393512A (en) 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
JPH0641454B2 (ja) 1985-02-27 1994-06-01 日産化学工業株式会社 ピリダジノン誘導体
JPS61260018A (ja) 1985-05-14 1986-11-18 Nissan Chem Ind Ltd 抗アレルギ−剤
TR22638A (tr) 1985-07-30 1988-01-29 Nissan Chemical Ind Ltd Piridazinon tuerevleri,bunlarin ve hasarat oeldueruecue bilesiklerin hazirlanmasina mahsus usul
JPH0739397B2 (ja) 1985-07-30 1995-05-01 日産化学工業株式会社 ピリダジノン誘導体および害虫防除剤
DE3688613T2 (de) * 1985-11-18 1994-01-13 Access Pharma Inc Polychelierende stoffe für abbildung- und spektralerhöhung (und spektrale verschiebung).
JPS6315974A (ja) 1986-07-09 1988-01-23 小泉コンピユ−タ−株式会社 ボ−リングゲ−ム点数表表示装置
US5252317A (en) * 1986-11-10 1993-10-12 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
US5567411A (en) * 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
JPS63159374A (ja) 1986-12-24 1988-07-02 Nissan Chem Ind Ltd ピリダジノン誘導体および殺虫、殺ダニ、殺線虫剤
JPS63159373A (ja) 1986-12-24 1988-07-02 Nissan Chem Ind Ltd ピリダジノン類および殺虫、殺ダニ、殺線虫剤
JPS63159372A (ja) 1986-12-24 1988-07-02 Nissan Chem Ind Ltd ピリダジノン化合物および殺虫、殺ダニ、殺線虫剤
DE3824210A1 (de) 1988-07-16 1990-01-18 Basf Ag 3(2h)-pyridazinonderivate zur bekaempfung von schnecken
IT1229684B (it) * 1989-04-05 1991-09-06 Mini Ricerca Scient Tecnolog Piridazinoni ad attivita' insetticida ed acaricida
JPH02279676A (ja) 1989-04-19 1990-11-15 Otsuka Chem Co Ltd ピリダジノン誘導体
US5087440A (en) * 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
GB8923843D0 (en) * 1989-10-23 1989-12-13 Salutar Inc Compounds
US5377681A (en) 1989-11-13 1995-01-03 University Of Florida Method of diagnosing impaired blood flow
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5679810A (en) * 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
JPH03220177A (ja) 1990-01-25 1991-09-27 Nissan Chem Ind Ltd 殺虫、殺ダニ剤組成物
WO1992017215A1 (en) 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Contrast media
US5250283A (en) * 1990-03-28 1993-10-05 Molecular Biosystems, Inc. Organic contrast agent analog and method of making same
GB9006977D0 (en) 1990-03-28 1990-05-23 Nycomed As Compositions
JPH04235975A (ja) 1991-01-21 1992-08-25 Nissan Chem Ind Ltd ピリダジノン誘導体および害虫防除剤
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5093105A (en) 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5306482A (en) 1991-04-09 1994-04-26 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
AU2462592A (en) 1991-08-29 1993-04-05 Mallinckrodt Medical, Inc. Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
US5169942A (en) 1991-11-21 1992-12-08 General Electric Company Method for making 2-(18F)fluoro-2-deoxy-D-glucose
DE69313278T2 (de) * 1992-06-17 1998-03-26 Procter & Gamble Nichtstechende zusammensetzungen mit kühleffekt
EP0627424A4 (en) 1992-12-03 1995-03-29 Otsuka Kagaku Kk PYRIDAZINE DERIVATIVES AND INCENTICIDES AND MITICIDES.
US5760191A (en) * 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
WO1994021653A1 (en) 1993-03-22 1994-09-29 General Electric Company Method for making 2-fluoro-2-deoxyglucose
CA2158249A1 (en) 1993-03-31 1994-10-13 James W. Brodack Radiopharmaceutical formulations having non-stannous reductants
US5417959A (en) * 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
GB9323028D0 (en) 1993-11-09 1994-01-05 Isis Innovation Asymmetric hydroboration
JPH07252236A (ja) 1994-01-28 1995-10-03 Takeda Chem Ind Ltd 抗癌剤
EP0665223A1 (en) 1994-01-28 1995-08-02 Takeda Chemical Industries, Ltd. Antitumor agent, novel 3(2H)-pyridazinone derivatives and their preparation
JPH10501218A (ja) 1994-06-03 1998-02-03 マリンクロッド・メディカル・インコーポレイテッド 迅速に消失するテクネチウム−９９ｍホスホネート骨格イメージング剤
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
EP0727225A3 (en) 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions and methods for directed ultrasonic imaging
US5587491A (en) 1995-03-15 1996-12-24 Regents Of The University Of Minnesota Method for the synthesis of bis-tetrahydrofuranyl Annonaceous acetogenins
US5801228A (en) * 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
US5811073A (en) 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US5827073A (en) * 1995-07-05 1998-10-27 Ludwig Institute For Cancer Research Photoreactive peptide derivatives
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5804161A (en) * 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
ES2206689T3 (es) * 1996-10-28 2004-05-16 Amersham Health As Agentes de contraste.
US6565889B2 (en) 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
JP4017758B2 (ja) * 1998-08-04 2007-12-05 高砂香料工業株式会社 冷感剤組成物
US6056939A (en) 1998-08-28 2000-05-02 Desreux; Jean F. Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals
AU1309100A (en) * 1998-09-29 2000-04-17 Merck & Co., Inc. Radiolabeled neurokinin-1 receptor antagonists
US6645508B1 (en) 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
US6878363B2 (en) * 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
RU2174779C1 (ru) * 2000-05-29 2001-10-20 Научно-исследовательский институт пищеконцентратной промышленности и специальной пищевой технологии Способ производства плодово-ягодного десерта
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
AU2001288899A1 (en) 2000-09-06 2002-03-22 The Scripps Research Institute Inhibitors of nadh:ubiquinone oxidoreductase
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
US7344702B2 (en) * 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US20030044354A1 (en) 2001-08-16 2003-03-06 Carpenter Alan P. Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
WO2003032912A2 (en) 2001-10-16 2003-04-24 Hypnion, Inc. Treatment of cns disorders using cns target modulators
AU2003217349B2 (en) * 2002-02-06 2008-05-22 The Johns Hopkins University Non-invasive diagnostic imaging technology for mitochondria using radiolabeled lipophilic salts
WO2003082350A2 (en) * 2002-03-29 2003-10-09 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
WO2003086476A1 (en) 2002-04-08 2003-10-23 Biostream, Inc. Technetium-labeled rotenone derivatives, and methods of use thereof
GB0229683D0 (en) 2002-12-20 2003-01-29 Imaging Res Solutions Ltd Preparation of radiopharmaceuticals
US7618975B2 (en) * 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2005007632A1 (en) 2003-07-18 2005-01-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
SG144160A1 (en) 2003-07-24 2008-07-29 Bracco Imaging Spa Stable radiopharmaceutical compositions and methods for their preparation
GB0317920D0 (en) 2003-07-31 2003-09-03 Amersham Plc Solid-phase synthesis
US7927616B2 (en) * 2004-01-16 2011-04-19 Thomas T. Yamashita Pesticide compositions and methods for their use
CA2552356C (en) 2004-02-24 2013-11-19 The General Hospital Corporation Catalytic radiofluorination
JPWO2005085200A1 (ja) 2004-03-05 2008-01-17 萬有製薬株式会社 ピリドン誘導体
AT500838B1 (de) 2004-04-20 2007-11-15 Veterinaermedizinische Uni Wie Multiple hse
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
US20060083681A1 (en) 2004-10-18 2006-04-20 Ajay Purohit Compounds for myocardial perfusion imaging
US7534418B2 (en) * 2004-12-10 2009-05-19 The Regents Of The University Of Michigan Imaging agents
KR100789847B1 (ko) 2004-12-15 2007-12-28 (주)퓨쳐켐 알코올 용매하에서 유기플루오로 화합물의 제조방법
EP1893244A4 (en) 2005-06-23 2009-06-24 Univ Emory CONTRAST AGENTS
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
JP2007112725A (ja) 2005-10-18 2007-05-10 Inst Nuclear Energy Research Rocaec 無支持体の１８Ｆで標識したアミノ酸Ｏ−（２−［１８Ｆ］ｆｌｕｏｒｏｅｔｈｙｌ）−Ｌ−Ｔｙｒｏｓｉｎｅの製造方法。
US7871623B2 (en) 2005-12-21 2011-01-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for imaging pain and stress in vivo
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
MX2008016344A (es) 2006-06-21 2009-02-12 Ge Healthcare Ltd Productos radiofarmaceuticos.
MX2009000334A (es) 2006-08-25 2009-01-28 Boehringer Ingelheim Int Nuevos derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos.
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
KR101810348B1 (ko) 2006-12-26 2017-12-18 랜티우스 메디컬 이메징, 인크. 심장 신경 분포의 영상화를 위한 리간드
JP5504563B2 (ja) 2006-12-27 2014-05-28 住友化学株式会社 組成物及び該組成物を用いてなる発光素子
GB0718386D0 (en) 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
KR101068835B1 (ko) 2007-10-26 2011-09-30 한국과학기술연구원 베타-아밀로이드 집적체 및 피브릴에 우수한 결합 친화도를가지는 이소인돌론 화합물 및 이의 제조 방법
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
WO2009103478A1 (en) 2008-02-19 2009-08-27 Boehringer Ingelheim International Gmbh Pyridone and pyridazinone derivatives as mch antagonists
WO2010011367A2 (en) 2008-02-22 2010-01-28 Illinois Institute Of Technology Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
ES2767973T3 (es) 2008-02-29 2020-06-19 Lantheus Medical Imaging Inc Agentes de contraste para aplicaciones que comprenden formación de imágenes de perfusión
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
EP2406233B1 (en) 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
CN107261159B (zh) 2009-04-15 2021-01-12 兰休斯医疗成像公司 使用抗坏血酸稳定化放射性药物组合物
CN101555232B (zh) 2009-05-21 2011-01-05 北京师范大学 氟-18标记哒嗪酮类化合物及制备方法和应用
JP2012532833A (ja) 2009-07-11 2012-12-20 バイエル ファーマ アクチエンゲゼルシャフト 非極性及び極性脱離基
TWI589302B (zh) 2010-02-08 2017-07-01 藍瑟斯醫學影像公司 用於合成造影劑及其中間體之方法及裝置
DE102010036356A1 (de) 2010-07-12 2012-01-12 Abx Advanced Biochemical Compounds Gmbh Vorrichtung zur Synthese radioaktiv markierter Verbindungen
JP5842594B2 (ja) 2010-12-27 2016-01-13 住友化学株式会社 ピリダジノン化合物、それを含有する除草剤及び有害節足動物防除剤
CN102336741B (zh) 2011-07-06 2013-04-10 北京师范大学 氟-18标记的心肌灌注显像剂及其制备方法和应用
CA2848147C (en) 2011-09-09 2021-08-24 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
AU2011379346B2 (en) 2011-10-21 2017-08-31 Lantheus Medical Imaging, Inc. Compositions comprising ascorbic acid and an imaging agent and related methods
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP2882863B1 (en) 2012-08-13 2021-07-14 The General Hospital Corporation System and method for quantitative mapping of mitocondrial complex 1

Also Published As

Publication number Publication date
CN102274527A (zh) 2011-12-14
US20180009763A1 (en) 2018-01-11
US9161997B2 (en) 2015-10-20
NO20170638A1 (no) 2006-11-08
WO2005079391A3 (en) 2006-02-16
CA2556213C (en) 2013-12-17
IN2012DN02610A (ro) 2015-09-04
BRPI0507684B1 (pt) 2021-02-23
IL228097A0 (en) 2013-09-30
EP1713512A2 (en) 2006-10-25
US7344702B2 (en) 2008-03-18
EP3385253A1 (en) 2018-10-10
US20190127333A1 (en) 2019-05-02
EP1713512B1 (en) 2018-01-10
US10889550B2 (en) 2021-01-12
CN1925878A (zh) 2007-03-07
KR101186449B1 (ko) 2012-09-27
KR20120031243A (ko) 2012-03-30
EP1713512A4 (en) 2009-01-07
CN1925878B (zh) 2011-10-12
KR20060122920A (ko) 2006-11-30
KR101386851B1 (ko) 2014-04-17
CA2828128C (en) 2016-11-22
IL177275A (en) 2013-11-28
US20120276006A1 (en) 2012-11-01
RU2457865C2 (ru) 2012-08-10
IL177275A0 (en) 2006-12-10
RU2648358C2 (ru) 2018-03-23
NO344857B1 (no) 2020-06-02
JP2013047277A (ja) 2013-03-07
SG149895A1 (en) 2009-02-27
CA2556213A1 (en) 2005-09-01
DK3385253T3 (da) 2021-06-28
WO2005079391A2 (en) 2005-09-01
MX348859B (es) 2017-06-30
CN102274527B (zh) 2015-04-29
CA2828128A1 (en) 2005-09-01
IL243840A0 (en) 2016-04-21
BRPI0507684A (pt) 2007-07-17
NO20064011L (no) 2006-11-08
AU2005214898B2 (en) 2011-01-06
RU2012113613A (ru) 2013-10-20
US20160130235A1 (en) 2016-05-12
US9718786B2 (en) 2017-08-01
BRPI0507684B8 (pt) 2021-07-27
ES2878171T3 (es) 2021-11-18
JP2014218525A (ja) 2014-11-20
US8226929B2 (en) 2012-07-24
US20210300878A1 (en) 2021-09-30
JP5847065B2 (ja) 2016-01-20
JP6124848B2 (ja) 2017-05-10
JP2007526916A (ja) 2007-09-20
ES2665687T3 (es) 2018-04-26
JP5417578B2 (ja) 2014-02-19
CA2944947A1 (en) 2005-09-01
DK1713512T3 (en) 2018-04-23
US20080112884A1 (en) 2008-05-15
EP3385253B1 (en) 2021-04-07
AU2005214898A1 (en) 2005-09-01
AU2005214898C1 (en) 2011-08-04
PT1713512T (pt) 2018-04-17
US10125106B2 (en) 2018-11-13
RU2006132814A (ru) 2008-03-20
IL228097A (en) 2016-02-29
US20050191238A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
IL243840A0 (en) Contrast agents for myocardial perfusion imaging
IL178911A0 (en) Contrast agents for myocardial perfusion imaging
GB0519391D0 (en) Imaging agents
EP1893244A4 (en) CONTRAST AGENTS
EP1893245A4 (en) RADIOACTIVELY MARKED PEGYLATION OF LIGANDS FOR USE AS A CONTRAST
GB2410566B (en) Imaging members
IL177078A0 (en) Gated imaging
GB0610395D0 (en) Novel imaging agents
CA2651257A1 (en) IMAGING WITH DOUBLE MODALITY
ZA200702843B (en) Compounds for myocardial perfusion imaging
GB0524987D0 (en) Novel imaging agents for fibrosis
EP1788946A4 (en) PICTURE SYSTEM
EP1788947A4 (en) PICTURE SYSTEM
GB0523506D0 (en) Novel in vivo imaging compounds
EP1638612A4 (en) COX-2-MADE DISPLAY AGENTS
EP1956978A4 (en) GHOST FOR IMAGING DIFFUSION TENSOR
HK1162139A1 (en) Myocardial perfusion imaging using adenosine receptor agonists
GB0512770D0 (en) Imaging compounds
GB0524991D0 (en) Novel imaging agents for fibrosis
GB0502277D0 (en) Novel imaging agents
EP1968442A4 (en) IN SITU HYPERPOLARIZATION OF IMAGING AGENTS
DE602005012474D1 (de) Bilderzeugung
GB0421308D0 (en) Enzyme inhibitor imaging agents
GB0613287D0 (en) Dye imaging agents
ZA200609031B (en) Contrast agents for myocardial perfusion imaging